GET DAILY SIGNALSABT vs MDT: Weighing Abbott Laboratories Against Medtronic
Key Takeaways
- Tickeron AI Verdict: MDT is the current favored ticker, reflecting stronger momentum, a steadier trend near its 52-week high, and fewer headline overhangs relative to ABT.
- ABT offers broad diversification across medical devices, diagnostics, nutrition, and pharmaceuticals, but recent performance has been weighed down by litigation costs and slowing growth in key product lines.
- MDT is a pure-play medical device leader that has re-accelerated organic growth and attracted a wave of analyst upgrades in recent months.
- Both companies compete directly in diabetes care and cardiovascular devices, but their market positioning and risk profiles differ meaningfully.
- For deeper coverage, explore ABT Major News and ABT Today's Price Move, along with MDT Major News and MDT Today's Price Move.
- To see how automated strategies are navigating this comparison and hundreds of others, explore Trending AI Robots.
Why Compare These Two Healthcare Names
ABT (Abbott Laboratories) and MDT (Medtronic plc) stand out as two of the most prominent players in the healthcare sector. Their shared focus on medical devices and diabetes technology makes them a logical pair for comparison. Investors seeking broad healthcare exposure might lean toward Abbott, while those preferring a specialized medical technology business often look at Medtronic. Here I review their recent results, business approaches, and risk factors to offer a clear perspective on how they stack up right now.
ABT Overview and Recent Performance
Abbott Laboratories operates across four main areas: medical devices, diagnostics, nutrition, and established pharmaceuticals. The medical device segment, anchored by the FreeStyle Libre continuous glucose monitoring system and an expanding electrophysiology portfolio, has driven much of the recent growth. In the latest quarter, the company delivered double-digit reported sales growth with solid comparable growth, helped by strength in cancer diagnostics through the Cologuard franchise. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Even so, the market reaction has been measured. Abbott lowered its full-year comparable sales guidance, citing slower momentum in diabetes care and electrophysiology. It also announced plans to spin off the nutrition business into a separate public company, which should sharpen focus but brings near-term execution questions. Earnings faced additional pressure from legal settlements related to preterm infant formula litigation. These elements have led to softer relative performance and more muted price momentum lately.
MDT Overview and Recent Performance
Medtronic plc ranks among the largest pure-play medical device companies, with operations spanning cardiovascular, neuroscience, medical-surgical, and diabetes segments. After a slower period, the company has regained commercial traction. Its most recent quarter topped revenue and adjusted EPS estimates, powered by gains in cardiovascular and diabetes, prompting management to raise the full-year organic revenue growth forecast.
Analyst sentiment toward MDT has turned more positive, with several firms raising price targets and a handful upgrading ratings in recent months. Fresh product developments, such as FDA clearance for the Hugo robotic-assisted surgery system in urologic procedures and the rollout of the MiniMed 780G insulin delivery system, have supported the outlook. The stock has held near the upper end of its recent range, showing more consistent trend behavior and improved market perception compared with prior stretches.
Head-to-Head Comparison
From a business standpoint, ABT trades diversification for added complexity, as nutrition, diagnostics, and pharmaceuticals provide stability yet also expose it to consumer trends, reimbursement changes, and litigation. MDT, on the other hand, operates as a focused medical technology company whose results tie more closely to procedure volumes and device innovation. On recent momentum, MDT has held the edge, trading near its 52-week high with stronger organic growth, while ABT has dealt with a guidance cut, legal costs, and slower growth in two previously high-growth areas. Valuation differences persist as well: Abbott has typically carried a premium multiple, whereas Medtronic has traded at a more modest level, though that spread has tightened with shifting sentiment. On risk, Abbott carries ongoing formula-litigation uncertainty and spin-off execution risk, while Medtronic must sustain above-average growth and protect margins amid higher investment spending.
Tickeron AI Verdict
Looking at factors such as trend consistency, relative momentum, catalyst visibility, and headline risk, Tickeron’s AI currently favors MDT over ABT. Medtronic’s steadier price trend near its 52-week high, improved organic growth, and supportive analyst environment stand in contrast to Abbott’s recent guidance adjustment, litigation overhang, and slowing growth in key segments. This view represents a probabilistic assessment of present conditions rather than a firm prediction, and relative positioning could change with new earnings, regulatory, or legal updates.
Exploring Automated Strategies
When evaluating setups like this one, I often turn to Tickeron’s AI Trading Bots for additional context on how data-driven approaches are handling similar names. The platform runs hundreds of bots across thousands of tickers, each tuned to different styles and timeframes. The Trending AI Robots section curates those showing strength in current conditions, offering a practical way to review automated strategies without sifting through the full catalog. Whether tracking healthcare names or broader markets, it provides a focused starting point for assessing these tools in action.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABT in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 04, 2026
ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 24 of the 42 cases the stock fell afterwards. This puts the odds of success at 57%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 14 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ABT as a result. In 43 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 36 of 54 cases over the following month. The odds of a continued upward trend are 67%.
ABT moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 58%.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 136 of 264 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 92 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care products
Industry MedicalNursingServices
Advertisement